All In Biotech

Drug Trial Radar · NCT05965700

NVG-291 in Spinal Cord Injury Subjects

A Randomized, Double-Blind, Placebo-Controlled Phase 1b/2a Study of NVG-291 in Spinal Cord Injury Subjects (CONNECT)

Last checked: Nov 19, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

24

Actual

Start

Aug 8, 2023

Primary completion

Dec 31, 2025

Study completion Jan 21, 2026

Sponsor

Lead sponsor
NervGen PharmaIndustry
Sponsor type
Industry
First posted
Jul 28, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Randomized, Double-Blind, Placebo-Controlled Phase 1b/2a Study of NVG-291 in Spinal Cord Injury Subjects

Conditions

  • Spinal Cord Injuries
  • Chronic Spinal Cord Injury
  • Subacute Spinal Cord Injury

Interventions

  • NVG-291Drug

    A once daily injection

  • Placebo InjectionDrug

    A once daily injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. ElectrophysiologicalTime frame: 12 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Shirley Ryan AbilityLab

    Chicago, Illinois

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.